# Lenalidomide and Paclitaxel in Prostate Cancer

> **NCT00933426** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00933426
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Terminated early due to slow accrual as Phase I dose escalation study.
- **Last updated:** 2016-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00933426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00933426, "Lenalidomide and Paclitaxel in Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00933426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*